Boston-based Seaport Therapeutics has raised $225m in a Series B funding round, led by General Atlantic. Seaport will use the funds to aid clinical testing of its lead drug candidate, SPT-300, which could improve current depression treatments. The SPT-300 leverages Seaport’s platform technology, Glyph, which designs oral drugs to make the active pharmaceutical ingredient more accessible in the body, reducing issues such as liver enzyme elevation.
Critical Fortinet FortiClient EMS 0-Day Vulnerability Actively Exploited in the Wild
Fortinet has issued an emergency hotfix after security researchers disclosed a critical zero-day vulnerability in FortiClient EMS that is already being actively exploited by threat
